A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™—the FUTURE study

A. Ghezzi, A. Bianchi, D. Baroncini, A. Bertolotto, S. Malucchi, V. Bresciamorra, R. Lanzillo, N. Milani, V. Martinelli, F. Patti, C. Chisari, M. Rottoli, M. Simone, D. Paolicelli, A. Visconti, FUTURE Study Group

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Besides the impact of disease per se, the use of immunomodulatory therapies in adolescents with relapsing-remitting multiple sclerosis (RRMS) may have an effect on quality of life (QL). The FUTURE (Quality of liFe in adolescent sUbjecTs affected by mUltiple sclerosis treated with immunomodulatoRy agEnt using self-injecting device) study was designed to evaluate the changes in QL of Italian adolescents with RRMS receiving treatment with IFN-β1a (Rebif; 22 μg), administered subcutaneously three times weekly using the RebiSmart™ electronic autoinjection device over a 52-week period. Fifty adolescents with RRMS were enrolled and 40 completed the study. Changes from baseline to end of treatment (EoT) in adolescent self-reported and parent-reported QL were assessed using the Pediatric Quality of Life Inventory Multidimensional Fatigue Scale (PedsQL), which has been validated for use in pediatric MS and for which an Italian version is available. The adolescent self-reported total PedsQL4.0 score and all of its subscales tended to increase from baseline to EoT, the only exception being “Emotional functioning.” In parent-reported measures, the total PedsQL4.0 score increased significantly from baseline to EoT (+ 5.27 points, p = 0.041). Significant increases were also evident for parent-reported “Psychosocial health summary score” (+ 5.90 points; p = 0.015) and “School functioning” (+ 7.84 points; p = 0.029). Our results indicate that adolescents with RRMS using the electronic injection device RebiSmart™ for self-administration of Rebif® can experience long-term improvements in QL.

Original languageEnglish
Pages (from-to)1999-2005
Number of pages7
JournalNeurological Sciences
Volume38
Issue number11
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

Interferons
Multiple Sclerosis
Observational Studies
Relapsing-Remitting Multiple Sclerosis
Quality of Life
Prospective Studies
Equipment and Supplies
Pediatrics
Self Administration
Immunomodulation
Therapeutics
Fatigue
Injections
Health

Keywords

  • Adherence
  • Interferon-beta
  • Pediatric multiple sclerosis
  • Quality of life

ASJC Scopus subject areas

  • Dermatology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™—the FUTURE study. / Ghezzi, A.; Bianchi, A.; Baroncini, D.; Bertolotto, A.; Malucchi, S.; Bresciamorra, V.; Lanzillo, R.; Milani, N.; Martinelli, V.; Patti, F.; Chisari, C.; Rottoli, M.; Simone, M.; Paolicelli, D.; Visconti, A.; FUTURE Study Group.

In: Neurological Sciences, Vol. 38, No. 11, 01.11.2017, p. 1999-2005.

Research output: Contribution to journalArticle

Ghezzi, A. ; Bianchi, A. ; Baroncini, D. ; Bertolotto, A. ; Malucchi, S. ; Bresciamorra, V. ; Lanzillo, R. ; Milani, N. ; Martinelli, V. ; Patti, F. ; Chisari, C. ; Rottoli, M. ; Simone, M. ; Paolicelli, D. ; Visconti, A. ; FUTURE Study Group. / A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™—the FUTURE study. In: Neurological Sciences. 2017 ; Vol. 38, No. 11. pp. 1999-2005.
@article{1c03d79931604215865fd881d1877547,
title = "A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™—the FUTURE study",
abstract = "Besides the impact of disease per se, the use of immunomodulatory therapies in adolescents with relapsing-remitting multiple sclerosis (RRMS) may have an effect on quality of life (QL). The FUTURE (Quality of liFe in adolescent sUbjecTs affected by mUltiple sclerosis treated with immunomodulatoRy agEnt using self-injecting device) study was designed to evaluate the changes in QL of Italian adolescents with RRMS receiving treatment with IFN-β1a (Rebif; 22 μg), administered subcutaneously three times weekly using the RebiSmart™ electronic autoinjection device over a 52-week period. Fifty adolescents with RRMS were enrolled and 40 completed the study. Changes from baseline to end of treatment (EoT) in adolescent self-reported and parent-reported QL were assessed using the Pediatric Quality of Life Inventory Multidimensional Fatigue Scale (PedsQL), which has been validated for use in pediatric MS and for which an Italian version is available. The adolescent self-reported total PedsQL4.0 score and all of its subscales tended to increase from baseline to EoT, the only exception being “Emotional functioning.” In parent-reported measures, the total PedsQL4.0 score increased significantly from baseline to EoT (+ 5.27 points, p = 0.041). Significant increases were also evident for parent-reported “Psychosocial health summary score” (+ 5.90 points; p = 0.015) and “School functioning” (+ 7.84 points; p = 0.029). Our results indicate that adolescents with RRMS using the electronic injection device RebiSmart™ for self-administration of Rebif{\circledR} can experience long-term improvements in QL.",
keywords = "Adherence, Interferon-beta, Pediatric multiple sclerosis, Quality of life",
author = "A. Ghezzi and A. Bianchi and D. Baroncini and A. Bertolotto and S. Malucchi and V. Bresciamorra and R. Lanzillo and N. Milani and V. Martinelli and F. Patti and C. Chisari and M. Rottoli and M. Simone and D. Paolicelli and A. Visconti and {FUTURE Study Group}",
year = "2017",
month = "11",
day = "1",
doi = "10.1007/s10072-017-3091-6",
language = "English",
volume = "38",
pages = "1999--2005",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "11",

}

TY - JOUR

T1 - A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™—the FUTURE study

AU - Ghezzi, A.

AU - Bianchi, A.

AU - Baroncini, D.

AU - Bertolotto, A.

AU - Malucchi, S.

AU - Bresciamorra, V.

AU - Lanzillo, R.

AU - Milani, N.

AU - Martinelli, V.

AU - Patti, F.

AU - Chisari, C.

AU - Rottoli, M.

AU - Simone, M.

AU - Paolicelli, D.

AU - Visconti, A.

AU - FUTURE Study Group

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Besides the impact of disease per se, the use of immunomodulatory therapies in adolescents with relapsing-remitting multiple sclerosis (RRMS) may have an effect on quality of life (QL). The FUTURE (Quality of liFe in adolescent sUbjecTs affected by mUltiple sclerosis treated with immunomodulatoRy agEnt using self-injecting device) study was designed to evaluate the changes in QL of Italian adolescents with RRMS receiving treatment with IFN-β1a (Rebif; 22 μg), administered subcutaneously three times weekly using the RebiSmart™ electronic autoinjection device over a 52-week period. Fifty adolescents with RRMS were enrolled and 40 completed the study. Changes from baseline to end of treatment (EoT) in adolescent self-reported and parent-reported QL were assessed using the Pediatric Quality of Life Inventory Multidimensional Fatigue Scale (PedsQL), which has been validated for use in pediatric MS and for which an Italian version is available. The adolescent self-reported total PedsQL4.0 score and all of its subscales tended to increase from baseline to EoT, the only exception being “Emotional functioning.” In parent-reported measures, the total PedsQL4.0 score increased significantly from baseline to EoT (+ 5.27 points, p = 0.041). Significant increases were also evident for parent-reported “Psychosocial health summary score” (+ 5.90 points; p = 0.015) and “School functioning” (+ 7.84 points; p = 0.029). Our results indicate that adolescents with RRMS using the electronic injection device RebiSmart™ for self-administration of Rebif® can experience long-term improvements in QL.

AB - Besides the impact of disease per se, the use of immunomodulatory therapies in adolescents with relapsing-remitting multiple sclerosis (RRMS) may have an effect on quality of life (QL). The FUTURE (Quality of liFe in adolescent sUbjecTs affected by mUltiple sclerosis treated with immunomodulatoRy agEnt using self-injecting device) study was designed to evaluate the changes in QL of Italian adolescents with RRMS receiving treatment with IFN-β1a (Rebif; 22 μg), administered subcutaneously three times weekly using the RebiSmart™ electronic autoinjection device over a 52-week period. Fifty adolescents with RRMS were enrolled and 40 completed the study. Changes from baseline to end of treatment (EoT) in adolescent self-reported and parent-reported QL were assessed using the Pediatric Quality of Life Inventory Multidimensional Fatigue Scale (PedsQL), which has been validated for use in pediatric MS and for which an Italian version is available. The adolescent self-reported total PedsQL4.0 score and all of its subscales tended to increase from baseline to EoT, the only exception being “Emotional functioning.” In parent-reported measures, the total PedsQL4.0 score increased significantly from baseline to EoT (+ 5.27 points, p = 0.041). Significant increases were also evident for parent-reported “Psychosocial health summary score” (+ 5.90 points; p = 0.015) and “School functioning” (+ 7.84 points; p = 0.029). Our results indicate that adolescents with RRMS using the electronic injection device RebiSmart™ for self-administration of Rebif® can experience long-term improvements in QL.

KW - Adherence

KW - Interferon-beta

KW - Pediatric multiple sclerosis

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85027841409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027841409&partnerID=8YFLogxK

U2 - 10.1007/s10072-017-3091-6

DO - 10.1007/s10072-017-3091-6

M3 - Article

VL - 38

SP - 1999

EP - 2005

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 11

ER -